Published in J Neurol Neurosurg Psychiatry on December 18, 2006
Early Parkinson's Disease (PD) Cross-Sectional (EPDX) | NCT00817453
Dopaminergic therapy affects learning and impulsivity in Parkinson's disease. Ann Clin Transl Neurol (2014) 1.41
Pharmacological treatment effects on eye movement control. Brain Cogn (2008) 1.30
Differential effects of dopaminergic therapies on dorsal and ventral striatum in Parkinson's disease: implications for cognitive function. Parkinsons Dis (2011) 1.13
Visual exploration of emotional facial expressions in Parkinson's disease. Neuropsychologia (2010) 0.94
Dopamine-mediated learning and switching in cortico-striatal circuit explain behavioral changes in reinforcement learning. Front Behav Neurosci (2011) 0.87
Eye movement impairments in Parkinson's disease: possible role of extradopaminergic mechanisms. BMC Neurol (2012) 0.86
Differential diagnostic value of eye movement recording in PSP-parkinsonism, Richardson's syndrome, and idiopathic Parkinson's disease. J Neurol (2009) 0.86
Remedial effects of motivational incentive on declining cognitive control in healthy aging and Parkinson's disease. Front Aging Neurosci (2010) 0.85
Impaired control of the oculomotor reflexes in Parkinson's disease. Neuropsychologia (2009) 0.84
Effect of subthalamic deep brain stimulation on turning kinematics and related saccadic eye movements in Parkinson disease. Exp Neurol (2012) 0.84
Effect of D-amphetamine on inhibition and motor planning as a function of baseline performance. Psychopharmacology (Berl) (2010) 0.84
Do eye movement impairments in patients with small vessel cerebrovascular disease depend on lesion load or on cognitive deficits? A video-oculographic and MRI study. J Neurol (2014) 0.82
Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy. Psychopharmacology (Berl) (2013) 0.80
Saccadic eye movements in Parkinson's disease. Indian J Ophthalmol (2014) 0.79
Changes to saccade behaviors in Parkinson's disease following dancing and observation of dancing. Front Neurol (2013) 0.79
Multiple step pattern as a biomarker in Parkinson disease. Parkinsonism Relat Disord (2009) 0.77
Changes in Timing and kinematics of goal directed eye-hand movements in early-stage Parkinson's disease. Transl Neurodegener (2013) 0.77
Cortical control of saccades in Parkinson disease and essential tremor. J Neural Transm (Vienna) (2012) 0.76
Ocular motor abnormalities in neurodegenerative disorders. Eye (Lond) (2014) 0.76
Pallidal Deep Brain Stimulation Improves Higher Control of the Oculomotor System in Parkinson's Disease. J Neurosci (2015) 0.76
The effects of unilateral versus bilateral subthalamic nucleus deep brain stimulation on prosaccades and antisaccades in Parkinson's disease. Exp Brain Res (2016) 0.75
Pramipexole Increases Go Timeouts but Not No-go Errors in Healthy Volunteers. Front Hum Neurosci (2016) 0.75
Constraining eye movement in individuals with Parkinson's disease during walking turns. Exp Brain Res (2016) 0.75
Response inhibition in Parkinson's disease: a meta-analysis of dopaminergic medication and disease duration effects. NPJ Parkinsons Dis (2017) 0.75
Slowed Prosaccades and Increased Antisaccade Errors As a Potential Behavioral Biomarker of Multiple System Atrophy. Front Neurol (2017) 0.75
Core assessment program for intracerebral transplantations (CAPIT). Mov Disord (1992) 5.51
Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex (2001) 3.67
Functional organization of human intraparietal and frontal cortex for attending, looking, and pointing. J Neurosci (2003) 3.17
'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. Brain (1988) 2.36
Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication. Neuropsychologia (2000) 2.26
Oculomotor evidence for neocortical systems but not cerebellar dysfunction in autism. Neurology (1999) 2.07
Eye movement control by the cerebral cortex. Curr Opin Neurol (2004) 2.01
Using saccades as a research tool in the clinical neurosciences. Brain (2003) 1.89
Impaired mesial frontal and putamen activation in Parkinson's disease: a positron emission tomography study. Ann Neurol (1992) 1.86
L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology (Berl) (1992) 1.41
Altered control of visual fixation and saccadic eye movements in attention-deficit hyperactivity disorder. J Neurophysiol (2003) 1.35
Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet (2002) 1.28
Parkinson's disease subtypes: clinical classification and ventricular cerebrospinal fluid analysis. Parkinsonism Relat Disord (2000) 1.17
Control of voluntary and reflexive saccades in Parkinson's disease. Exp Brain Res (1999) 1.16
Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease. Drugs Aging (2000) 1.09
Voluntary control of saccadic eye movements in patients with schizophrenic and affective disorders. J Psychiatr Res (1990) 1.01
Saccadic latency distributions in Parkinson's disease and the effects of L-dopa. Exp Brain Res (2006) 0.98
Antisaccades and smooth pursuit eye movements in schizophrenia. Biol Psychiatry (1995) 0.97
Nicotine reduces antisaccade errors in task impaired schizophrenic subjects. Prog Neuropsychopharmacol Biol Psychiatry (2004) 0.96
Sequences of memory-guided saccades in Parkinson's disease. Ann Neurol (1994) 0.94
Control of saccades in Parkinson's disease. Brain Cogn (2002) 0.93
Automatic orienting of visuospatial attention in Parkinson's disease. Neuropsychologia (2001) 0.91
Dissociating cognitive deficits involved in voluntary eye movement dysfunctions in Parkinson's disease patients. Neuropsychologia (2005) 0.90
Spatial selective attention in schizophrenic, affective disorder, and normal subjects. Schizophr Res (1996) 0.85
Disturbed striatoprefrontal mediated visual behaviour in moderate to severe parkinsonian patients. J Neurol Neurosurg Psychiatry (1997) 0.83
Antisaccadic effects of a dopamine agonist as add-on therapy in advanced Parkinson's patients. Neuropsychobiology (2000) 0.83
Nicotine improves antisaccade task performance without affecting prosaccades. Hum Psychopharmacol (2004) 1.47
Comparison of shape encoding in primate dorsal and ventral visual pathways. J Neurophysiol (2006) 1.41
Phosphorylated α-synuclein in Parkinson's disease. Sci Transl Med (2012) 1.29
Attention and memory-related responses of neurons in the lateral intraparietal area during spatial and shape-delayed match-to-sample tasks. J Neurophysiol (2005) 1.26
Shape selectivity in primate frontal eye field. J Neurophysiol (2008) 1.06
Disruption of reflexive attention and eye movements in an individual with a collicular lesion. J Clin Exp Neuropsychol (2006) 1.00
Age-related reduction in estrogen receptor-mediated mechanisms of vascular relaxation in female spontaneously hypertensive rats. Hypertension (2003) 0.99
Eye tracking dysfunction in schizophrenia: characterization and pathophysiology. Curr Top Behav Neurosci (2010) 0.97
Nicotine reduces antisaccade errors in task impaired schizophrenic subjects. Prog Neuropsychopharmacol Biol Psychiatry (2004) 0.96
Acute bilateral basal ganglia lesions and chorea in a diabetic-uremic patient on dialysis. Arch Neurol (2010) 0.93
Assessment of medication management ability in middle-aged and older adults with bipolar disorder. J Clin Psychopharmacol (2008) 0.92
Performance-based and subjective measures of functioning in middle-aged and older adults with bipolar disorder. J Nerv Ment Dis (2009) 0.92
Dissociating cognitive deficits involved in voluntary eye movement dysfunctions in Parkinson's disease patients. Neuropsychologia (2005) 0.90
Spatial modulation of primate inferotemporal responses by eye position. PLoS One (2008) 0.90
Social orienting: reflexive versus voluntary control. Vision Res (2010) 0.89
Evidence of cognitive dysfunction after soccer playing with ball heading using a novel tablet-based approach. PLoS One (2013) 0.89
Population coding of visual space: modeling. Front Comput Neurosci (2011) 0.88
α-Synuclein and anti-α-synuclein antibodies in Parkinson's disease, atypical Parkinson syndromes, REM sleep behavior disorder, and healthy controls. PLoS One (2012) 0.87
Shape effects on reflexive spatial selective attention and a plausible neurophysiological model. Vision Res (2010) 0.85
Reduced volume of the putamen in REM sleep behavior disorder patients. Parkinsonism Relat Disord (2010) 0.84
Consensus panel guidelines for the use of intrathecal baclofen therapy in poststroke spastic hypertonia. Top Stroke Rehabil (2006) 0.84
Reflexive and volitional saccades: biomarkers of Huntington disease severity and progression. J Neurol Sci (2011) 0.84
Delayed onset of inhibition of return in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2002) 0.83
Cytokines disrupt intracellular patterns of Parkinson's disease-associated proteins alpha-synuclein, tau and ubiquitin in cultured glial cells. Brain Res (2008) 0.83
Isolated central nervous system histoplasmosis presenting with ischemic pontine stroke and meningitis in an immune-competent patient. JAMA Neurol (2013) 0.83
The role of response in spatial attention: direct versus indirect stimulus-response mappings. Vision Res (2002) 0.82
Benign tremulous parkinsonism? Arch Neurol (2006) 0.82
Inflammatory cells and cytokines in the olfactory bulb of a rat model of neuroinflammation; insights into neurodegeneration? J Interferon Cytokine Res (2013) 0.81
Population coding and the labeling problem: extrinsic versus intrinsic representations. Neural Comput (2013) 0.81
Fluorescence microscopy and 3D image reconstruction of cytokine initiated disruption of the Parkinson disease associated proteins alpha-synuclein, tau and ubiquitin in cultured glial cells. Cytokine (2009) 0.81
Localization of calcitonin gene-related peptide in cardiomyocytes: comparison of neonatal and dedifferentiating cells to adult myocytes. Peptides (2005) 0.81
Altered nigrostriatal and nigrocortical functional connectivity in rapid eye movement sleep behavior disorder. Sleep (2013) 0.80
Intrathecal baclofen therapy slows progressive disability in multiple system atrophy. Neuromodulation (2011) 0.78
Voluntary spatial attention has different effects on voluntary and reflexive saccades. ScientificWorldJournal (2003) 0.78
Effects of haloperidol on cognition in schizophrenia patients depend on baseline performance: a saccadic eye movement study. Prog Neuropsychopharmacol Biol Psychiatry (2011) 0.78
Effects of adjunct valproic acid on clinical symptoms and saccadic eye movements in schizophrenia. Hum Psychopharmacol (2011) 0.78
Oculomotor executive function abnormalities with increased tic severity in Tourette syndrome. J Child Psychol Psychiatry (2014) 0.77
Novel n-back spatial working memory task using eye movement response. Behav Res Methods (2011) 0.77
Shape effects on reflexive spatial attention are driven by the dorsal stream. Vision Res (2012) 0.77
Determination of the site of action of calcitonin gene-related peptide in the alteration of intracellular calcium levels in adult and neonatal rodent myocytes. Peptides (2005) 0.77
Dissociating sensory and motor components of inhibition of return. ScientificWorldJournal (2006) 0.77
Can mild cognitive impairment in Parkinson disease predict the development of dementia? JAMA Neurol (2013) 0.75
Monkeys in space: primate neural data suggest volumetric representations. Behav Brain Sci (2013) 0.75
Postencephalitic hemiparkinsonism: clinical imaging correlation. Arch Neurol (2008) 0.75
Acute and Subacute Presentations of Cerebral Edema following Deep Brain Stimulation Lead Implantation. Stereotact Funct Neurosurg (2017) 0.75